Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

There Will Be Healthy Competition Between India And China - Two Emerging Biotech Superpowers - Says Reinhard Gluck, Research Head At Zydus Cadila And Chairman, Swiss Biotech Association

This article was originally published in PharmAsia News

Executive Summary

Reinhard Gluck, chairman of the Swiss Biotech Association, had lucrative offers pouring in after Crucell sold Italy-based Etna Biotech, the research arm for which he worked, to India's Zydus Cadila in 2008. Gluck, known for his ability in developing vaccines, preferred to stay on with his new employer, impressed by the opportunities that could emerge from the Indian connection. Excited by Cadila's commitment to the long haul, Gluck says it would not have been as good a call to work for any other established bigger multinational company. On the sidelines of the recent BioPharma Asia conference in Singapore, Gluck sat down with PharmAsia News' India bureau cheif to speak on issues ranging from funding of biotech initiatives to future vaccines and the research outlook in Asia.

You may also be interested in...



Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Billion In Sales By 2015

Cadila is said to have allocated $20 million for its Vermont-headquartered unit Zydus Technologies to work on a range of compounds to be delivered via transdermal patches.

Backed By Biosimilars, Vaccines, Transdermals And Respiratory Drugs, India's Cadila Sets Sights On $3 Bil In Sales By 2015

AHMEDABAD, India - In a few months India's Zydus Cadila will join a handful of elite Indian companies like Dr. Reddy's and Cipla that managed to surpass the magic $1 billion mark in annual sales. Cadila says it has a comprehensive blueprint ready to cruise to $3 billion by 2015

Latest News
UsernamePublicRestriction

Register

SC074539

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel